IDH-mutant gliomas are relatively uncommon in pediatric and adolescent/young adult (AYA) populations (Pollack et al., 2011; Yeo et al., 2023) and consequently, standardized management guidelines akin to those established for adults are currently lacking. This evidence concerns the gene IDH2 and central nervous system cancer.